Full-Time
Develops EEG devices for brain activity monitoring
$100k - $180k/yr
Mid, Senior
Denver, CO, USA
Get referrals →
You have ways to get a Ceribell referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 5 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Ceribell develops medical devices that use electroencephalogram (EEG) technology to monitor brain activity, specifically through their Ceribell EEG Headband and Recorder. These devices are intended for trained healthcare providers in professional settings and help gather critical data for diagnosing neurological conditions. Unlike some devices, the Ceribell EEG Recorder does not provide diagnostic conclusions or alerts; it simply collects data for healthcare professionals to interpret. The company aims to support timely treatment decisions, especially in urgent cases like Nonconvulsive Status Epilepticus (NCSE), and generates revenue by selling these devices to healthcare providers.
Company Size
201-500
Company Stage
Series C
Total Funding
$171M
Headquarters
Mountain View, California
Founded
2014
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Unlimited Paid Time Off
Paid Holidays
Parental Leave
Annual Bonus Opportunity
Company Equity
Phone/Internet Stipend
CeriBell's (NASDAQ:CBLL) lock-up period ends on April 9th, allowing major shareholders and insiders to trade shares. The company issued 10,606,060 shares in its IPO on October 11th, raising $180 million at $17 per share. Analysts have given CBLL a consensus "Buy" rating with a $32.50 price target. The stock opened at $18.19, with a 52-week range of $17.24 to $32.75. Recent earnings missed estimates, reporting a loss of $0.40 per share on $18.53 million revenue.
—Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions (“Ceribell”), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. “Ms
Ceribell, a former Fierce Medtech Fierce 15 honoree, has been developing a point-of-care electroencephalography platform that combines a disposable, brain-reading headset with artificial intelligence-powered algorithms that help detect hidden seizures-also known as electrographic status epilepticus, or ESE.
CeriBell, a medical device maker with an EEG platform that uses AI to monitor patient seizures, announced terms for its IPO on Monday.
Healthcare sales veteran to lead sales strategies and initiatives to propel continued commercial growthSUNNYVALE, Calif., April 2, 2024 /PRNewswire/ -- Today, Ceribell, Inc.®, the developer of the first AI-powered point-of-care EEG diagnostic system, announced the appointment of Sean Manni as Senior Vice President of Sales. In this role, Mr. Manni will lead Ceribell's commercial sales organization as it continues to expand its U.S. footprint."Sean brings an impressive blend of accomplishments, strategy, and leadership that will undoubtedly elevate our entire commercial organization," said Ceribell co-founder and CEO Jane Chao, Ph.D. "His guidance will be instrumental in developing and executing our plans to further expand our market presence in the U.S., ultimately benefiting patients by increasing access to our groundbreaking technology.""Joining Ceribell represents a unique opportunity to collaborate with an exceptional leadership and sales team," said Manni. "I am deeply committed to leveraging my experience in healthcare sales to further innovate Ceribell's sales strategies and ensure our revolutionary AI-powered point-of-care EEG solutions reach patients in need."Mr